

FEB 5 1997

RETURNED TO DEPARTMENTAL LIBRARY
RETOURNER A LA BIBLIOTHÈQUE DU MINISTÈRE

3 5036 01029682 3

CANADA

I N V E S T M E N T N E W S

DECEMBER 1996

Glaxo Wellcome
invests \$120 millionin new
manufacturing/
science
complex
near Toronto

Initial production tests and quality certification trials are under way at Glaxo Wellcome Inc.'s new integrated manufacturing and product development centre at Mississauga, Ontario.

When the \$120 million complex comes into full operation in mid-1997, it will produce a range of Glaxo products including Zantac® (for ulcer treatment), Imitrex® (migraine), Zofran® (cancer therapy side-effects), Zovirax® (shingles) and 3TC® (HIV/AIDS).

Glaxo Wellcome Inc. is the Canadian subsidiary of Glaxo Holdings p.l.c., of the U.K., the world's largest pharmaceutical company in terms of sales.

Paul N. Lucas, President and CEO of Glaxo Wellcome Inc., points out that the company already exports over half its output to the United States. He says: "Construction of the new facility will lead to an expansion of our already significant exports to the U.S. and also to new global product mandates within Glaxo Wellcome."

In an interview with *Canada Investment News*, Corporate Communications Manager Tim Turnbull

Please see **GLAXO** page 2

Also in this issue...

Lafarge's \$130 million expansion	2
Alcatel's Quebec City plant	
-wired for \$21 million upgrade	3
SPM's new Canadian	
plastic moulding plant	4
Keane Inc. chooses Halifax as	
software development centre	5
New KPMG study shows US\$	
goes further in Canada	5
Degussa picks Quebec City	6
Galderma builds a \$35 million	
Canadian base	8
New Hewlett-Packard	
Canada expansion	9
Italy's Cristini invests \$20 million	
in Quebec plant	10
Study shows cost advantages	
to eastern Canada	11
Growing with Canada	12